# US 2021/0267674 A1 · Methods and devices for localized disease treatment by ablation

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0267674 A1
- Document ID: US20210267674A1
- Status: Published application
- Kind: A1
- Application number: 17/306,541
- Filed: 2021-05-03
- Published: 2021-09-02
- Earliest claimed: 2012-04-27
- Assignees: Medtronic Ardian Luxembourg S.a.r.l.
- Applicants: Medtronic Ardian Luxembourg S.a.r.l.
- Inventors: Ayala Hezi-Yamit; Susan Edwards; Carol Sullivan
- Web page: https://patentgrep.com/patent/US20210267674A1

## CPC

- A61B 18/1492: {having a flexible, catheter-like structure, e.g. for heart ablation (A61B18/1477 takes precedence)}
- A61B 18/24: with a catheter (A61B18/26, A61B18/28 take precedence)
- A61N 7/02: Localised ultrasound hyperthermia
- A61B 17/22004: {using mechanical vibrations, e.g. ultrasonic shock waves (A61B17/225 takes precedence)}
- A61B 18/02: by cooling, e.g. cryogenic techniques
- A61B 18/1815: {using microwaves}
- A61B 18/20: using laser
- A61B 90/39: {Markers, e.g. radio-opaque or breast lesions markers}
- A61B 2018/00214: {Expandable means emitting energy, e.g. by elements carried thereon}
- A61B 2018/0022: {Balloons}
- A61B 2018/00404: {Blood vessels other than those in or around the heart}
- A61B 2018/00434: {Neural system}
- A61B 2018/00511: {Kidney}
- A61B 2018/00577: {Ablation}
- A61B 2018/00791: {Temperature}
- A61B 2018/00839: {Bioelectrical parameters, e.g. ECG, EEG}
- A61B 2018/00863: {Fluid flow}
- A61B 2018/0212: {using an instrument inserted into a body lumen, e.g. catheter}
- A61B 2018/1807: {using light other than laser radiation}
- A61B 2018/1861: {with an instrument inserted into a body lumen or cavity, e.g. a catheter}
- A61B 2090/064: {for measuring force, pressure or mechanical tension}
- A61B: DIAGNOSIS; SURGERY; IDENTIFICATION (usefulness limited to only animals A61D)
- A61N: ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY (measurement of bioelectric currents A61B; surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body A61B18/00; anaesthetic apparatus in general A61M; incandescent lamps H01K; infrared radiators for heating H05B)

## Abstract

Provided herein are methods, systems, and devices for increasing heat shock protein expression and treating conditions for which increased heat shock protein expression is expected to be beneficial using thermal ablation.

## Claims

### Claim at position 1

1-11. (canceled)

### Claim 12

A method of treating a human patient diagnosed with a cancerous tumor, the method comprising:
intravascularly positioning a catheter carrying a neuromodulation treatment device adjacent to a target sympathetic nerve innervating tissue proximate the tumor in the patient; and
delivering energy to the target sympathetic nerve via the neuromodulation assembly to reduce sympathetic nerve activity in the target sympathetic nerve,
wherein reducing sympathetic nerve activity in the target sympathetic nerve results in a therapeutically beneficial treatment of the tumor.

### Claim 13 (depends on 12)

The method of claim 12, wherein reducing sympathetic nerve activity in the target sympathetic nerve results in an increase in an HSP expression level, and wherein after delivering energy to the target sympathetic nerve, the method further comprises:
quantifying the HSP expression level; and
comparing the HSP expression level to a pre-determined threshold expression level for the HSP,
wherein the HSP expression level is beneficial in the treatment of the tumor if the HSP expression level is greater than the pre-determined threshold expression level.

### Claim 14 (depends on 13)

The method of claim 13, wherein the HSP expression level includes one or more of an HSP mRNA level, an HSP protein level, a level of secreted HSP protein and a level of HSP activity.

### Claim 15 (depends on 12)

The method of claim 12, wherein the cancerous tumor is identified as a cancer for which increased HSP expression is expected to be beneficial.

### Claim 16 (depends on 12)

The method of claim 12, wherein the cancerous tumor is in the kidney of the patient, and wherein the neuromodulation treatment device is positioned within the renal artery.

### Claim 17 (depends on 12)

The method of claim 12, wherein reducing sympathetic nerve activity in the target sympathetic nerve comprises at least partially ablating the target sympathetic nerve.

### Claim 18 (depends on 12)

The method of claim 12, wherein reducing sympathetic nerve activity in the target sympathetic nerve comprises increasing an HSP expression level in the tissue proximate the tumor in the patient.

### Claim 19 (depends on 12)

The method of claim 12, wherein a therapeutically beneficial treatment of the tumor includes one or more of slowing the onset or rate of development of the tumor, reducing the risk of spread of the tumor, preventing or delaying the development of symptoms associated with the tumor, reducing or ending symptoms associated with the tumor, generating a complete or partial regression of the tumor, or a combination thereof.
